Abstract
Pulmonary arterial hypertension (PAH) is a progressive, debilitating, and potentially fatal disease. Symptoms of PAH are non-specific and may include dyspnea, fatigue, chest discomfort, pre-syncope/syncope, palpitations, lower extremity swelling, non-specific gastro-intestinal symptoms, weight loss, and cyanosis. Pulmonologists are increasingly involved in the care of these patients, whether at the initial presentation and diagnosis, medication titration, or for symptom relief and management of complications. The pulmonologist and intensivist also frequently care for patients that are at an increased risk of developing PAH, such as patients with cirrhosis, hypoxic lung disease, scleroderma, sickle cell disease, and HIV to name a few. An echocardiogram, although often inaccurate in estimating the right-sided heart pressures, is the best screening tool for PAH. A right heart catheterization is the gold standard for diagnosing PAH. Supplemental therapies may include oxygen, diuretics, and anticoagulation. In addition to the limited role of calciumchannel blockers, PAH-specific therapies fall into one of 3 families for now: Phospho-diesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclins. The current estimated 2 year survival of PAH patients now exceeds 90%, compared to a historical median survival of 2-3 years.
Keywords: Pulmonary hypertension, diagnosis, management, Dana Point, ERA, PDE5 inhibitor, prostanoid, Clinical Presentation, Symposium, fatal disease, pulmonary artery, anti-inflammatory molecules, hepatitis C
Current Respiratory Medicine Reviews
Title: Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Volume: 7 Issue: 4
Author(s): Wassim H. Fares, Hubert James Ford and Robert M. Aris
Affiliation:
Keywords: Pulmonary hypertension, diagnosis, management, Dana Point, ERA, PDE5 inhibitor, prostanoid, Clinical Presentation, Symposium, fatal disease, pulmonary artery, anti-inflammatory molecules, hepatitis C
Abstract: Pulmonary arterial hypertension (PAH) is a progressive, debilitating, and potentially fatal disease. Symptoms of PAH are non-specific and may include dyspnea, fatigue, chest discomfort, pre-syncope/syncope, palpitations, lower extremity swelling, non-specific gastro-intestinal symptoms, weight loss, and cyanosis. Pulmonologists are increasingly involved in the care of these patients, whether at the initial presentation and diagnosis, medication titration, or for symptom relief and management of complications. The pulmonologist and intensivist also frequently care for patients that are at an increased risk of developing PAH, such as patients with cirrhosis, hypoxic lung disease, scleroderma, sickle cell disease, and HIV to name a few. An echocardiogram, although often inaccurate in estimating the right-sided heart pressures, is the best screening tool for PAH. A right heart catheterization is the gold standard for diagnosing PAH. Supplemental therapies may include oxygen, diuretics, and anticoagulation. In addition to the limited role of calciumchannel blockers, PAH-specific therapies fall into one of 3 families for now: Phospho-diesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclins. The current estimated 2 year survival of PAH patients now exceeds 90%, compared to a historical median survival of 2-3 years.
Export Options
About this article
Cite this article as:
H. Fares Wassim, James Ford Hubert and M. Aris Robert, Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights, Current Respiratory Medicine Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339811798281197
DOI https://dx.doi.org/10.2174/157339811798281197 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Prone Position on Myocardial Perfusion SPECT Interpretation in Women with Suspected Coronary Disease
Current Medical Imaging Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart
Current Cardiology Reviews Cardiac SPECT-CT and PET-CT Imaging
Current Medical Imaging Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study
Current Alzheimer Research Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke
Current Neurovascular Research The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Colchicine in the Prevention of Cerebrovascular Ischemia
Current Pharmaceutical Design Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes
Current Alzheimer Research Treating Cancer in Older and Oldest Old Patients
Current Pharmaceutical Design Physiological and Pharmacological Regulation of Hepatic 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Hepatocyte Growth Factor and Macrophage-stimulating Protein “Hinge” Analogs to Treat Pancreatic Cancer
Current Cancer Drug Targets Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity
Current Vascular Pharmacology Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Natural Alpha-Glucosidase Inhibitors: Therapeutic Implication and Structure- Activity Relation Ship
Letters in Drug Design & Discovery Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews